Cannabinoid receptors are packed into the same brain circuits that Parkinsonâs disease damages. This overlap has given researchers about twenty years of hope. By the latest count, it has also produced eleven randomised controlled trials. When those trials are combined, cannabinoids show no benefit for movement. Some possible benefits for anxiety, sleep and quality of life have not yet been tested in trials designed to confirm them. This article explains why the theory did not lead to better movement and where the real open question lies.
This is not medical advice. It is also not a reason to change any Parkinsonâs medicine. Levodopa and dopamine agonists, the main Parkinsonâs drugs, have a narrow safe dose range, and sudden changes are dangerous. In Thailand, cannabis flower is a controlled herb. It is dispensed only with a PT 33 (ภ.ŕ¸.33) prescription from an authorised practitioner.
1. Why the Idea Made Sense
Parkinsonâs disease is a brain disease that gets worse over time. It happens because the nerve cells that make dopamine slowly die. Dopamine is a chemical messenger that the brain needs to control movement. These cells sit in a small area deep in the brain called the substantia nigra.
The loss of dopamine causes the movement symptoms: tremor, stiff muscles (rigidity), slow movement and poor balance. Patients also live with many non-motor symptoms, which are symptoms that do not involve movement. These include poor sleep, anxiety, depression, pain, constipation and changes in thinking and memory.
The body has its own cannabinoid signalling network, called the endocannabinoid system. One of its main receptors is CB1. It is the receptor that THC (tetrahydrocannabinol), the main intoxicating compound in cannabis, acts on. CB1 receptors are packed into the basal ganglia, a group of deep-brain circuits that start movements and keep them smooth.
CB1 receptors are especially dense in the striatum, the part of the basal ganglia that receives most incoming signals. Parkinsonâs damages this same circuit. The endocannabinoid system helps regulate movement through these pathways. Because the receptors sit inside the damaged circuit, it made sense to test whether acting on them helps.
Huntingtonâs disease is an inherited brain disease that also damages the striatum, and people often cite it as supporting evidence. The human trials there are also few. In the 2022 review described below, only one of three randomised trials in Huntingtonâs reported symptom relief. That trial used nabilone, a man-made prescription medicine that acts like THC. Huntingtonâs has its own forum article: Cannabis in ALS and Huntingtonâs Disease.
The idea is based on real anatomy. When it was tested on movement in patients, though, it did not hold up. A good theory and a result in patients are two different things, and this topic shows the difference clearly.
What you can do: Someone may tell you that cannabis âworks for Parkinsonâs because the receptors are in the right placeâ. Before you accept that, ask what the trials in patients showed. Section 2 gives you those results to compare against.
2. What the Trials Found
How to read the trial numbers
- A randomised controlled trial uses chance to split patients into two groups. One group gets the medicine. The other gets a dummy treatment (placebo) or a comparison treatment. Because chance decides the groups, any difference between them is most likely caused by the medicine.
- A systematic review collects every trial on one question. A meta-analysis then combines (âpoolsâ) their results into one overall estimate.
- The standardised mean difference (SMD) puts results measured on different rating scales onto one common scale. Zero means the medicine and the comparison gave the same result.
- The 95% confidence interval is the range where the true effect most likely lies. If the range includes zero, the trials cannot tell the medicine apart from no effect at all.
- The p-value shows how easily a difference this size could appear by chance if the medicine did nothing. By common convention, a p-value above 0.05 is ânot statistically significantâ.
The 2022 review: seven trials in Parkinsonâs
Oikonomou and Jost published a review in the Journal of Neural Transmission in 2022. It covered randomised trials of cannabis-based medicines in movement disorders, the diseases that mainly affect movement. They found seven randomised trials in Parkinsonâs disease. The trials used different cannabis preparations.
In the table, the âmain outcomeâ is the result a trial was designed to measure.
| What was measured | Result across the trials |
|---|---|
| Movement symptoms | No improvement in the 2 trials where movement was the main outcome |
| Levodopa-induced dyskinesia (involuntary twisting movements caused by long-term levodopa use) | Only 1 of 3 trials with this as the main outcome showed a reduction (nabilone) |
| Quality of life | Improved in the nabilone group (1 trial) |
| Anxiety, and tremor triggered by anxiety | Reduced by cannabidiol (CBD), a non-intoxicating cannabis compound (1 trial) |
| Anxiety and sleep problems | Improved by nabilone (1 trial) |
The 2026 update: eleven trials
Messak and colleagues published an updated systematic review and meta-analysis of randomised trials in Acta Neurologica Belgica in 2026. They found eleven randomised trials. Six of them reported data in a form that could be pooled. The combined results were:
| Area measured | SMD (95% confidence interval) | p-value |
|---|---|---|
| Overall disease severity | 0.16 (â0.13 to 0.44) | 0.27 |
| Movement, as examined by a doctor | â0.08 (â0.35 to 0.20) | 0.57 |
| Movement problems in daily life | â0.08 (â0.49 to 0.33) | 0.71 |
| Non-motor symptoms | â0.03 (â0.72 to 0.67) | 0.94 |
Every confidence interval includes zero. This does not mean a small benefit. It means that no benefit could be detected in any of the four areas. The authors concluded that cannabinoids have not shown a significant benefit in Parkinsonâs disease. They also said the findings should be read with caution, and they named nabilone as worth testing in its own dedicated trial.
The authors also ran a sensitivity analysis, which means repeating the calculation with one trial left out to see whether the result changes. The trial they left out was by Peball and colleagues, published in Annals of Neurology in 2020. That trial also tested nabilone, for non-motor symptoms. The review reports that without that trial, the non-motor estimate was largely driven by nabilone: SMD 0.34 (95% CI â0.19 to 0.88), p = 0.21. The review abstract does not say which remaining trial gave this nabilone estimate. The range still includes zero, so this result is not statistically significant either.
What you can do: When you see a claim about cannabis and Parkinsonâs, check three things. How many patients were studied? Was there a comparison group? Did the movement scores actually change? So far, the trials in these two reviews do not support any claim of better movement.
3. The Patients Who Got Worse
Promotional material often presents cannabis as a treatment for tremor. One of the earliest clinical reports points the other way, and any fair summary should include it.
In 1986, Consroe and colleagues ran a small open-label study of cannabidiol in dystonia. In an open-label study, everyone knows what they are taking, and there is no comparison group. Dystonia is a movement disorder in which muscles tighten on their own and hold twisted postures. Two of the five patients also had parkinsonian features (Parkinson-like movement signs).
At cannabidiol doses above 300 mg per day, both patients got worse. Their hypokinesia (reduced, slowed movement) increased. Their resting tremor, which is shaking while the limb is at rest, also increased.
Two patients in a study without a comparison group do not prove that cannabidiol harms Parkinsonâs patients in general. They do show the direction the response can take. Patients do not all respond the same way, and some respond badly. A pooled result near zero with a wide range fits this pattern. Some patients improve, some get worse, and on average the effect is zero.
A report that mentions only the hoped-for tremor benefit leaves out the patients whose tremor got worse. That makes the report incomplete.
Translatorâs note: Homemade cannabis oil, and oil sold without a lab certificate, does not show how much cannabidiol or THC each drop contains. The 300 mg per day in this study shows that the dose can change the outcome. If a family member uses a cannabinoid under a doctorâs care, use only a product whose content is stated on a certificate of analysis. Write down every dose.
What you can do: If a person with Parkinsonâs starts a cannabinoid under medical supervision, record their tremor every day in a simple diary. Start one week before the first dose so there is a baseline to compare with. If tremor or slowness gets worse, tell the neurologist (the brain and nerve specialist) promptly. The diary shows when the change started.
4. Where the Possible Benefit Actually Is
Reading the two reviews together shows a pattern. Apart from one nabilone trial on dyskinesia, every positive result is non-motor: anxiety, sleep and quality of life. None of the pooled movement scores changed.
There is a likely explanation that has nothing to do with dopamine. Parkinsonâs tremor is well known to get worse with stress and anxiety and to settle when the patient is calm. A drug that reduces anxiety therefore reduces the extra tremor that anxiety causes. It does this without changing the underlying movement disorder. The cannabidiol trial described exactly this: less anxiety and less anxiety-triggered tremor.
If this explanation is right, three things follow:
- Patients who feel a real benefit are not imagining it.
- The benefit is likely to be in symptoms linked to anxiety and sleep, not in the Parkinsonâs movement problems themselves.
- The fair way for a prescriber to try a cannabinoid is a trial aimed at one named non-motor symptom with a clear endpoint. An endpoint is a specific result agreed in advance, such as a sleep score after four weeks. A trial aimed at tremor is not supported by the evidence.
These non-motor signals come from single small trials and one sensitivity analysis that was not statistically significant. They remain untested, not confirmed.
Translatorâs note: A trial aimed at one symptom gives the family and the doctor a clear answer about whether the cannabinoid helped. In Thailand, a family can prepare for this before the first appointment with a PT 33 prescriber or the treating neurologist. The preparation is a record of the one symptom they hope to change.
What you can do: Before asking a doctor about a cannabinoid, choose one symptom to change, such as trouble falling asleep, waking at night or anxiety. Rate it from 0 to 10 every day for two weeks, and bring the record to the appointment. The doctor can then decide whether a trial makes sense. Later, you will both be able to see whether it worked.
5. Why Parkinsonâs Patients Face Extra Risks
Parkinsonâs patients face more of the usual cannabinoid risks than almost any other group, and these risks add up. Other patient groups that need similar care are covered in Contraindications and Cautions.
Low blood pressure on standing, and falls. Three separate factors each make a fall more likely:
- Poor balance is a core feature of Parkinsonâs.
- Orthostatic hypotension is common in Parkinsonâs. It is a drop in blood pressure on standing up, and it causes dizziness. It comes from the disease itself and also as a side effect of dopamine medicines.
- THC lowers blood pressure on standing.
Translatorâs note: In the hot season in Thailand and Southeast Asia, temperatures of 30â35 °C make people sweat more, and older people often drink too little. Losing body fluid also makes dizziness on standing more likely. At home, help the patient stand up slowly, in stages. Keep water within reach all day. Keep the path to the bathroom clear and lit at night. Ask the doctor whether to check the patientâs blood pressure both lying down and standing.
Psychosis. Psychotic symptoms are common in Parkinsonâs, especially seeing things that are not there (visual hallucinations). They become more common later in the disease and with dopamine treatment. They are one of the strongest predictors that a patient will need nursing-home care. THC can trigger psychotic symptoms. This is the most serious specific concern for this group. For this reason, the treating neurologist should manage any cannabinoid use.
Thinking and memory. Many patients develop cognitive impairment or dementia as the disease progresses. THC in general impairs attention, working memory and reaction time while it is acting. This adds to problems the patient may already have.
Many medicines at once. Patients may already take several medicines:
- levodopa;
- dopamine agonists;
- MAO-B inhibitors, which slow the breakdown of dopamine;
- amantadine, another Parkinsonâs medicine;
- antidepressants;
- sleeping pills.
The drowsiness from these medicines and from cannabinoids adds together. Cannabinoids are also broken down in the liver by the cytochrome P450 enzymes, which break down many of these medicines too. This shared route is a source of drug interactions.
Each of these cautions applies to cannabinoid use in general. Parkinsonâs patients often have most of them at the same time.
What you can do: Write a list of every medicine, supplement and herbal product the patient takes, with the doses. Take it to the neurologist before any cannabinoid is started. Ask specifically about the risk of falls, hallucinations and drowsiness.
6. A Fair Summary
- The mechanism is real. CB1 receptors sit in the striatum, and the endocannabinoid system helps regulate movement.
- The trials are real too. There are eleven of them, and no pooled analysis shows a benefit for movement.
- The positive signals that remain are in anxiety, sleep and quality of life. No trial built to test them has confirmed them yet.
- Two documented patients got worse.
- The trials are small, so the reviewers urge caution rather than calling the question closed.
These results do not show that cannabinoids are useless for every Parkinsonâs patient. They also do not show a hidden treatment. They show that two shortcuts are unreliable. The first is the mechanism: it predicted better movement, and the trials could not find it. The second is the personal success story: it cannot show whether the benefit was in the tremor itself or in the anxiety around it.
What you can do: Judge any claim by trial results in patients, not by brain diagrams or single stories. When you share information with a patient or family, include both the pooled trial results and the two patients who got worse.
7. The Rules in Thailand
Cannabis flower (ŕ¸ŕšŕ¸ŕ¸ŕ¸ŕ¸ŕ¸ŕ¸ąŕ¸ŕ¸ŕ¸˛) is a controlled herb under the Notification of the Ministry of Public Health Re: Controlled Herbs (Cannabis), B.E. 2568. The notification was issued under the Thai Traditional Medicine Protection Act B.E. 2542 (1999) and took effect on 26 June 2025. Flower may be sold only with a PT 33 (ภ.ŕ¸.33) prescription from an authorised practitioner. Each prescription covers no more than 30 days. Advertising and online sale of flower are prohibited.
In 2026, two ministerial regulations of B.E. 2569 changed the licensing rules:
- The Ministerial Regulation on Cannabis or Hemp Extracts B.E. 2569 took effect on 26 April 2026. Licences for extracts with more than 0.2% THC are open only to three groups: Thai juristic persons that are not âforeignâ under the Foreign Business Act B.E. 2542, state agencies and the Thai Red Cross Society.
- The Ministerial Regulation on Controlled Herbs (No. 2) B.E. 2569 took effect on 30 April 2026. It tightens the licence criteria for cannabis flower.
Check the current requirements with the prescriber. A separate Cannabis Control Act is still only a draft. The Cabinet approved the draft on 22 September 2026 and sent it to the House of Representatives. It is not law yet.
Parkinsonâs patients have a high risk of falls and psychosis, and they take many medicines, as Section 5 explains. For this group, the prescriberâs assessment is not a formality.
Translatorâs note: Many readers of this forum are growers. A relative may ask you for flower or homemade oil for a parent with Parkinsonâs. Under Section 78 of the 1999 Act, selling or processing a controlled herb without a licence (Section 46) carries up to 1 year in prison, a fine of up to 20,000 baht, or both. The safer route for the patient is also the legal one. Send the family to an authorised PT 33 prescriber. That way, the prescriber and the neurologist can check the patientâs full medicine list.
Translatorâs note: Some products and services mentioned here may not yet be available in Thailand. We could not confirm whether nabilone, the drug most often named in the trials above, is registered or available in Thailand. We also do not list which cannabis-based medicines are registered in Thailand or which public hospitals run cannabis clinics, because we could not confirm a current list. A practical first step is to ask the hospital where the patient is already treated. Ask whether it has a cannabis clinic or can refer the patient to one. Bring the medicine list and the two-week symptom diary.
What you can do: If a family member with Parkinsonâs wants to try a cannabinoid, prepare the medicine list and the symptom diary. Discuss both with the treating neurologist first. Then get any product through a PT 33 prescriber, never through a private grower or an online seller.
Share Your Experience
Has a person with Parkinsonâs in your care tried a cannabinoid under medical supervision? Please describe what changed in a reply below. Say whether the tremor itself changed, or the sleep and anxiety around it. That difference is the main open question in this field. Patientsâ own descriptions are one of the few places where it can be observed. Please do not name sellers or offer products here, because the advertising rules for cannabis flower also apply on this forum.
References
- Oikonomou P, Jost WH (2022). Randomized controlled trials on the use of cannabis-based medicines in movement disorders: a systematic review. Journal of Neural Transmission 129(10):1247â1256. doi:10.1007/s00702-022-02529-x
- Messak M, Abdelmageed A, Abbas AN, Mandour Y, Talkhan A, Eltohami MF, Kanaan D, Alfahmi FK, Saeed HT, Hamzeh LH, Taman L, Negida A (2026). Therapeutic effects of cannabinoids on Parkinsonâs disease: an updated systematic review and meta-analysis of randomized controlled trials. Acta Neurologica Belgica, published online 15 May 2026. doi:10.1007/s13760-026-03082-0
- Consroe P, Sandyk R, Snider SR (1986). Open label evaluation of cannabidiol in dystonic movement disorders. International Journal of Neuroscience 30(4):277â282. doi:10.3109/00207458608985678
- Peball M, Krismer F, Knaus H-G, et al. (2020). Non-Motor Symptoms in Parkinsonâs Disease are Reduced by Nabilone. Annals of Neurology 88(4):712â722. doi:10.1002/ana.25864. The trial left out in the Messak et al. sensitivity analysis.
This article is general educational information from the Asiannabis Community, not medical advice. Never change Parkinsonâs medication except under the direction of your neurologist.